Convergent Coexpression Reveals Shared Biological Mechanisms Underlying Common and Rare Variant Risk in Six Neuropsychiatric Disorders

Why It Matters

Linking common and rare genetic signals through convergent co‑expression uncovers core disease biology, accelerating target prioritization for neuropsychiatric therapeutics.

Key Takeaways

• Convergent co‑expression links GWAS and rare‑variant genes
• Top convergent genes capture most SNP and burden heritability
• Shared genes are evolutionarily constrained and drug‑target enriched
• Synaptic vesicle transport and astrocyte pathways common across disorders
• PoPS yields strongest convergence signal among GWAS methods

Pulse Analysis

Convergent co‑expression offers a systems‑level bridge between genome‑wide association studies and rare‑variant burden analyses, sidestepping the logistical hurdles of large‑scale CRISPR perturbations. By leveraging high‑quality dorsolateral prefrontal cortex data from the CommonMind Consortium and complementary GTEx brain regions, the authors quantified how risk genes co‑regulate across the transcriptome. This meta‑analytic framework aggregates co‑expression signals from multiple disorders, delivering a statistically robust map of shared downstream effects that traditional single‑variant approaches miss.

The analysis revealed that genes in the top decile of convergence explain the bulk of both common‑variant SNP heritability and rare‑variant burden heritability for several disorders, notably schizophrenia, bipolar disorder and Alzheimer’s disease. These genes are enriched for loss‑of‑function intolerance and intersect with FDA‑approved drug targets, underscoring their therapeutic relevance. Functional annotation highlighted recurrent biological themes—synaptic vesicle transport, neuronal development, and astrocyte activation—suggesting that disparate neuropsychiatric conditions converge on a limited set of cellular pathways.

For drug discovery, the findings provide a prioritized list of candidates that are supported by orthogonal genetic evidence, improving confidence in target validation. The cross‑disorder convergence also hints at the feasibility of repurposing existing neuropsychiatric agents across disease boundaries. Future work can extend this approach to single‑cell atlases and longitudinal expression datasets, refining the temporal and cellular specificity of convergent mechanisms and guiding precision‑medicine strategies for complex brain disorders.